8-Piperazinyl-2,3-dihydropyrrolo[3,2-g]isoquinolines: Potent, selective, orally bioavailable 5-HT1 receptor ligands

Bioorganic and Medicinal Chemistry Letters

Volumn 15, Issue 19, 2005, Pages 4370-4374

  Heightman, Tom D ^a   Gaster, Laramie M ^a   Pardoe, Sarah L ^a   Pilleux, Jean Pierre ^a   Hadley, Michael S ^a   Middlemiss, Derek N ^a   Price, Gary W ^a   Roberts, Claire ^a   Scott, Claire M ^a   Watson, Jeannette M ^a   Gordon, Laurie J ^a   Holland, Vicky A ^a   Powles, Jenifer ^a   Riley, Graham J ^a   Stean, Tania O ^a   Trail, Brenda K ^a   Upton, Neil ^a   Austin, Nigel E ^a   Ayrton, Andrew D ^a   Coleman, Tanya ^a   Cutler, Leanne ^a   more..

^a GLAXOSMITHKLINE   (United Kingdom)

Author keywords

5 HT1A; 5 HT1B; 5 HT1D; Receptor antagonist

Indexed keywords

3 (2 DIMETHYLAMINOETHYL) 4 CHLORO 5 PROPOXYINDOLE; ADRENERGIC RECEPTOR; DOPAMINE RECEPTOR; ISOQUINOLINE DERIVATIVE; LIGAND; SB 272183; SEROTONIN 1A AGONIST; SEROTONIN 1A ANTAGONIST; SEROTONIN 1B AGONIST; SEROTONIN 1B ANTAGONIST; SEROTONIN 1D AGONIST; SEROTONIN 1D ANTAGONIST; UNCLASSIFIED DRUG;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; CLONE; CONTROLLED STUDY; DOG; DRUG ACTIVITY; DRUG BIOAVAILABILITY; DRUG POTENCY; DRUG RECEPTOR BINDING; DRUG SELECTIVITY; DRUG SYNTHESIS; ELECTRIC SHOCK; GUINEA PIG; HYPOTHERMIA; MONKEY; NONHUMAN; RAT; SEIZURE; SUBSTITUTION REACTION;

ADMINISTRATION, ORAL; ANIMALS; BIOLOGICAL AVAILABILITY; BRAIN CHEMISTRY; ISOQUINOLINES; LIGANDS; RATS; RECEPTOR, SEROTONIN, 5-HT1A; RECEPTOR, SEROTONIN, 5-HT1B; RECEPTOR, SEROTONIN, 5-HT1D; RECEPTORS, SEROTONIN; SEROTONIN AGONISTS; SEROTONIN ANTAGONISTS; STRUCTURE-ACTIVITY RELATIONSHIP;

EID: 23944511176     PISSN: 0960894X     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.bmcl.2005.06.042     Document Type: Article

References (18)

1. P.J. Cowen J.P. Feighner W.F. Boyer Selective Serotonin Re-uptake Inhibitors 1996 John Wiley & Sons Chichester 63 86
2. R. Craven, D. Grahame-Smith, and N. Newberry Eur. J. Pharmacol. 271 1994 R1
3. S. Haj-Dahmane, M. Hamon, and L. Lanfumey Neuroscience 41 1991 495
4. J.S. Sprouse, and G.K. Aghajanian Synapse 1 1987 3
5. C. Roberts, J. Watson, M. Burton, G. Price, and B. Jones Br. J. Pharmacol. 117 1996 384
6. G. Engel, M. Gothert, D. Hoyer, E. Schlicker, and K. Hillenbrand Naunyn-Schmiederberg's Arch. Pharmacol. 332 1986 1
7. P. Bonaventure, P. Voorn, W.H.M.L. Luyten, M. Jurzak, A. Schotte, and J.E. Leysen Neuroscience 9 1998 641
8. P. Bonaventure, X. Langlois, and J.E. Leysen Neurosci. Lett. 254 1998 113
9. J.F. Cryan, and B.E. Leonard Human Psychopharmacology 15 2000 113
10. F. Artigas TIPS 14 1993 262
11. J.F. Czachura, and K. Rasmussen Naunyn-Schmiederbergs Arch. Pharmacol. 362 2000 266
12. C. Moret, and M. Briley Eur. J. Pharmacol. 180 1990 351
13. Procedures for cell firing and electrically stimulated release described in: J. Watson, C. Roberts, C. Scott, I. Kendall, L. Collin, N. Day, M.H. Harries, E. Soffin, C.H. Davies, A.D. Randall, T.D. Heightman, L. Gaster, P. Wyman, C. Parker, G.W. Price, and D.N. Middlemiss Br. J. Pharmacol. 133 2001 797
14. Chenard, B.L.; Macor, J.E.; Segelstein, B.E.; PCT Int. Appl. WO9421619; Chem. Abstr. 1994, 122, 314570.
15. G. Menozzi, L. Mosti, and P. Schenone J. Heterocycl. Chem. 24 1987 1669
16. DMPK procedures. Clearance and brain penetration determination, iv dosing in male Sprague-Dawley rats, constant infusion over 1 h to achieve target dose of 1 mg free base/kg; oral dosing, solution or suspension administered at target dose of 3 mg free base/kg. Blood and brain homogenate samples analysed by HPLC/MS/MS
17. Procedures for electroshock seizure threshold experiments described in: T.O. Stean, A.R. Atkins, C.A. Heidbreder, L.P. Quinn, B.K. Trail, and N. Upton Br. J. Pharmcol 144 2005 628
18. Procedure for SKF-99101-induced hypothermia described in: J.J. Hagan, P.D. Slade, L. Gaster, P. Jeffrey, J.P. Hatcher, and D.N. Middlemiss Eur. J. Pharmacol. 331 1997 169